Treatment of mice with an osteopontin-neutralizing antibody to target leukemia cell–ECM niche interactions sensitize dormant cells to chemotherapy highlighting the potential of targeting ECM-cancer cell interactions to kill cancer cells. This evidence concerns the gene SPP1 and leukemia.